{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Watanabe K"],"funding":["Financial Support: This study is financially supported by AstraZeneca."],"pagination":["e046451"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8728446"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(1)"],"pubmed_abstract":["<h4>Introduction</h4>Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is widely used as the first-line treatment for EGFR mutation-positive non-small cell lung cancer (NSCLC). Nevertheless, most cases ultimately acquire resistance to osimertinib, and no effective treatment has been currently established for cases having progressive disease (PD) with osimertinib. In clinical practice, EGFR-TKI therapy could be continued beyond response evaluation criteria in solid tumours (RECIST)-defined PD cases when they are clinically stable. Currently, the progression pattern of osimertinib and criteria for identifying patients who might benefit from osimertinib beyond PD are unknown. In addition, the efficacy and safety of osimertinib as the firs"],"journal":["BMJ open"],"pubmed_title":["Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study."],"pmcid":["PMC8728446"],"funding_grant_id":["ESR-18-13948"],"pubmed_authors":["Naka G","Kishi K","Ohashi Y","Kunitoh H","Yoh K","Watanabe K","Usui K","Hosomi Y","Uemura K"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study.","description":"<h4>Introduction</h4>Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is widely used as the first-line treatment for EGFR mutation-positive non-small cell lung cancer (NSCLC). Nevertheless, most cases ultimately acquire resistance to osimertinib, and no effective treatment has been currently established for cases having progressive disease (PD) with osimertinib. In clinical practice, EGFR-TKI therapy could be continued beyond response evaluation criteria in solid tumours (RECIST)-defined PD cases when they are clinically stable. Currently, the progression pattern of osimertinib and criteria for identifying patients who might benefit from osimertinib beyond PD are unknown. In addition, the efficacy and safety of osimertinib as the firs","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-19T18:06:00.922Z","creation":"2022-02-11T15:23:57.297Z"},"accession":"S-EPMC8728446","cross_references":{"pubmed":["34983748"],"doi":["10.1136/bmjopen-2020-046451"]}}